PAGSEG Inc vs Dr. Reddy's Laboratories Ltd Common Stock — how do they compare? PAGSEG Inc trades at $10.83 (market cap $3.03B), while Dr. Reddy's Laboratories Ltd Common Stock trades at $12.75 (market cap $10.78B). The key difference: Dr. Reddy's Laboratories Ltd Common Stock is far larger — about 3.6× PAGSEG Inc's market cap, and PAGSEG Inc pays the higher dividend (10.19%). Which is the better fit depends on your goals — on Pluang, investors hold PAGSEG Inc for 27 Days and Dr. Reddy's Laboratories Ltd Common Stock for 0 Days on average.
| PAGS | RDY | |
|---|---|---|
Market Cap | $3.03B | $10.78B |
Volume | 2,770,540 | 2,724,343 |
Sector | Industrials | Health |
52-Week High | $12.00 | $15.38 |
52-Week Low | $8.44 | $11.38 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | $11.16B | $10.68B |
Dividend Yield | 10.19% | 0.65% |
Signals from Pluang's Aura AI — not financial advice
PAGS trades at $10.99, down 1.35% on the day, with a bullish technical signal from moving averages but overbought short-term RSI readings. The company reported a Q2 2026 EPS beat of $0.41 vs. $0.389 expected, with revenue growth to $20.6B in 2026 and a net income margin of 10.45%. A dividend of $0.28 is scheduled for payment on September 30, 2026.
The stock presents a value opportunity with low P/E (7.31) and P/S (0.76) ratios, supported by strong analyst consensus (62.5% buy ratings) and a $10.70 price target. Key risks include macroeconomic pressures in Brazil and elevated credit losses, but robust cash flow and banking growth underpin long-term potential.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.
Read more on RDY →